Health & Fitness
Fri, July 30, 2010Thu, July 29, 2010Wed, July 28, 2010Tue, July 27, 2010Mon, July 26, 2010Fri, July 23, 2010Thu, July 22, 2010Wed, July 21, 2010Tue, July 20, 2010Mon, July 19, 2010Sun, July 18, 2010Sat, July 17, 2010Fri, July 16, 2010Thu, July 15, 2010Wed, July 14, 2010Tue, July 13, 2010Mon, July 12, 2010Inspire Announces Date for Conference Call and Webcast to Discuss Second Quarter 2010 Financial Results
Published in Health and Fitness on Thursday, July 22nd 2010 at 3:41 GMT by Market Wire
DURHAM, N.C.--([ BUSINESS WIRE ])--Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that it plans to report second quarter 2010 financial results on Thursday, August 5, 2010 before the market opens. Inspire's President and CEO, Adrian Adams, and Executive Vice President and CFO, Thomas R. Staab, II, will host a conference call and live webcast with an accompanying slide presentation on Thursday, August 5, 2010 at 8:00 a.m. ET.
The live webcast and replay will be available on Inspire's website at [ www.inspirepharm.com ]. The webcast will include audio of the conference call and a slide presentation to be reviewed during the call. To access the conference call, U.S. participants may call (877) 648-7970 and international participants may call (706) 902-0415. The conference ID number is 88702441. A telephone replay of the conference call will be available until August 12, 2010. To access this replay, U.S. participants may call (800) 642-1687 and international participants may call (706) 645-9291. The conference ID number is 88702441.
About Inspire
Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspirea™s goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical, scientific and commercial expertise. The most advanced compounds in Inspirea™s clinical pipeline are denufosol tetrasodium for cystic fibrosis and PROLACRIAa" (diquafosol tetrasodium ophthalmic solution) 2% for dry eye, which are both in Phase 3 development, and AZASITE®(azithromycin ophthalmic solution) 1% for blepharitis, which is in Phase 2 development. Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT®(epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% for dry eye. For more information, visit [ www.inspirepharm.com ].
